

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

MONTANI 1



Section 1. Identifying Info	rmation						
1. Given Name (First Name) David	2. Surnam	ne (Last Name) II	1		3. Date 31-January-2019		
4. Are you the corresponding author?	Yes	<b>√</b> No	Correspond Marc Hum	_	r's Name		
5. Manuscript Title Seeing the forest for the (arterial) tre	e: vascular pru	uning & the C	OPD pulmona	ıry vascula	ır phenotype		
6. Manuscript Identifying Number (if you	u know it)						
Section 2. The Work Under	r Considerat	ion for Pub	lication				
Did you or your institution <b>at any time</b> ro any aspect of the submitted work (include				-	•		
statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No							
ŕ							
Section 3. Relevant financi	ial activities	outside th	e submitted	work.			
Place a check in the appropriate box of compensation) with entities as de	scribed in the	instructions.	Use one line fo	or each en	tity; add as many lines as	you need by	
clicking the "Add +" box. You should Are there any relevant conflicts of int		·	-	iuring the	: 30 months prior to put	nication.	
If yes, please fill out the appropriate							
		Dougonal N	lon-Financial	7			
Name of Entity	Grant •	Fees?	Support?	Other •	Comments		
Actelion	<b>✓</b>	<b>✓</b>					
Bayer	<b>✓</b>	$\checkmark$					
GSK		$\checkmark$					
Pfizer		$\checkmark$					
BMS		$\checkmark$					
MSD		<b>√</b>					

MONTANI 2



Section 4. Intellectual Property Patents & Copyrights						
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No						
Section 5. Relationships not covered above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/circumstances are present (explain below):						
✓ No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Statement						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						
Dr. MONTANI reports grants and personal fees from Actelion, grants and personal fees from Bayer, personal fees from GSK, personal fees from Pfizer, personal fees from BMS, personal fees from MSD, outside the submitted work; .						

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

MONTANI 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Weatherald 1



Section 1.	Identifying Inform	ation					
1. Given Name (Fir Jason	rst Name)	2. Surnan Weather	ne (Last Name) ald			3. Date 31-January-2019	
4. Are you the cor	orresponding author? Yes Von Corresponding Author's Name  Marc Humbert					s Name	
5. Manuscript Title Seeing the forest for the (arterial) tree: vascular pruning & the COPD pulmonary vascular phenotype							
6. Manuscript Ider	ntifying Number (if you kr	now it)					
Section 2.	The Work Under Co	onsiderat	ion for Pub	lication			
any aspect of the s statistical analysis, Are there any relo	ubmitted work (including	but not lim				., commercial, private fou y design, manuscript pre	
Section 3.	Relevant financial	activities	outside the	submitted v	work.		
of compensation clicking the "Add Are there any rele	) with entities as descri	bed in the port relationest?	instructions. nships that w 'es	Use one line fo vere <b>present d</b>	r each enti	l relationships (regardle ty; add as many lines as 16 months prior to pul	s you need by
Name of Entity		Grant?	Personal N Fees?	on-Financial Support	Other?	Comments	
Actelion Pharmaceuti	icals	<b>✓</b>	<b>✓</b>	<b>✓</b>			
Bayer			$\checkmark$	$\checkmark$			
Novartis			$\checkmark$				
Canadian Vascular Ne	etwork	✓					
European Respiratory	Society	<b>✓</b>					
Canadian Thoracic So	ciety	<b>✓</b>					

Weatherald 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Weatherald reports grants, personal fees and non-financial support from Actelion Pharmaceuticals, personal fees and non-financial support from Bayer, personal fees from Novartis, grants from Canadian Vascular Network, grants from European Respiratory Society, grants from Canadian Thoracic Society, outside the submitted work; .

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Weatherald 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

## Identifying information.

## 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	ation			
1. Given Name (F Marc	irst Name)	2. Surname (Last N Humbert	lame)	3. Date 27-January-2019	
4. Are you the co	rresponding author?	✓ Yes No			
5. Manuscript Tit Seeing the fores	le st for the (arterial) tree: v	rascular pruning &	the COPD pulmona	ry vascular <sub>l</sub>	phenotype
6. Manuscript Ide Not yet assigne	entifying Number (if you kn d	ow it)			
Section 2.	The Work Under Co	onsideration for	Publication		
any aspect of the statistical analysis Are there any re	submitted work (including	but not limited to gi			t, commercial, private foundation, etc.) for y design, manuscript preparation,
Section 3.	Relevant financial	activities outsid	e the submitted	work.	
of compensation clicking the "Add Are there any re	n) with entities as descri	bed in the instruct port relationships the est?  Yes	ions. Use one line fo	or each entit	I relationships (regardless of amount ty; add as many lines as you need by 66 months prior to publication.
Name of Entity		Grant? Person	Non-Financial Support?	Other?	Comments
Actelion				CC GS In tri re se	IH has relationships with drug ompanies including Actelion, Bayer, SK, Merck and United Therapeutics addition to being investigator in ials involving these companies, elationships include consultancy ervice and membership of scientific dvisory boards.



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Bayer	<b>√</b>	<b>√</b>			MH has relationships with drug companies including Actelion, Bayer, GSK, Merck and United Therapeutics In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
GSK	<b>√</b>	✓			MH has relationships with drug companies including Actelion, Bayer, GSK, Merck and United Therapeutics In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
Merck		<b>✓</b>			MH has relationships with drug companies including Actelion, Bayer, GSK, Merck and United Therapeutics In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
United Therapeutics		<b>✓</b>			MH has relationships with drug companies including Actelion, Bayer, GSK, Merck and United Therapeutics In addition to being investigator in trials involving these companies, relationships include consultancy service and membership of scientific advisory boards.
Section 4. Intellectual Propert					



Cartion F	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
•	orts personal fees from Actelion, grants and personal fees from Bayer, grants and personal fees from GSK, om Merck, personal fees from United Therapeutics, outside the submitted work.

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.